Treatment for COVID-19—a cohort study from Northern Italy

Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of to...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Scientific reports Ročník 11; číslo 1; s. 20964 - 4
Hlavní autori: Guglielmetti, Lorenzo, Aschieri, Daniela, Kontsevaya, Irina, Calabrese, Francesco, Donisi, Alessandra, Faggi, Alberto, Ferrante, Patrizia, Fronti, Elisa, Gerna, Laura, Leoni, Maria Cristina, Paolillo, Franco, Ratti, Giovanna, Ruggieri, Alessandro, Sacchini, Daria, Scotti, Marta, Valdatta, Caterina, Stabile, Marco, Taliani, Gloria, Codeluppi, Mauro
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London Nature Publishing Group UK 25.10.2021
Nature Publishing Group
Nature Portfolio
Predmet:
692/308/174
692/699/255/2514
Antibiotics
Antiviral agents
Antiviral drugs
Azithromycin
Cohort analysis
Coronaviruses
Corticosteroids
COVID-19
Drug dosages
Heparin
Human health and pathology
Humanities and Social Sciences
Life Sciences
Molecular weight
Monoclonal antibodies
multidisciplinary
Science
Science (multidisciplinary)
Survival
Italy
Epidemiology
Viral infection
ISSN:2045-2322, 2045-2322
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of tocilizumab and of high doses of low molecular weight heparin, but not of antivirals (either alone or in combination), azithromycin, and any corticosteroid, was independently associated with lower mortality. Our results support further clinical evaluation of high doses of low molecular weight heparin and tocilizumab as COVID-19 therapeutics.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-00243-4